Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy

Synergistic drug combinations can extend the use of poly­(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To identify new synergistic combinations for PARPi, we screened a “micro-library” comprising a mix of comme...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2023-05, Vol.66 (10), p.6922-6937
Hauptverfasser:	Yusoh, Nur Aininie, Tiley, Paul R., James, Steffan D., Harun, Siti Norain, Thomas, Jim A., Saad, Norazalina, Hii, Ling-Wei, Chia, Suet Lin, Gill, Martin R., Ahmad, Haslina
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Cell Line, Tumor DNA Female Humans Ovarian Neoplasms - drug therapy Phthalazines - pharmacology Phthalazines - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Ruthenium - pharmacology Ruthenium - therapeutic use Zebrafish
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!